An interventional study of Virtual Reality Based Progressive Muscle Relaxation and Face-to-Face Progressive Muscle Relaxation in Pre-Eclampsia, Maternal Health and Relaxation, sponsored by Istanbul University - Cerrahpasa. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.
Sponsored by Istanbul University - Cerrahpasa · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Pre-Eclampsia with a site in Turkey — 11 open to participants now, 11 under way, none of them phase 3. Pre-Eclampsia · Turkey.
Among the 50 studies in Pre-Eclampsia with a site in Turkey, this one is the 5th largest by planned enrollment of the 19 interventional ones that give a count, is one of 5 that started in 2025, is one of 17 with no phase, reaches primary completion later than 8 of the 10 other live ones, and was the 40th registered.
918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.
Browse Pre-Eclampsia studies →11 of the 50 studies in Pre-Eclampsia with a site in Turkey are open now. Recruiting first, the newest first:
Muğla Sıtkı Koçman University · Sites in Turkey
Ages 18–45 · Women only · Healthy volunteers
Samsun University · Sites in Turkey
Ages 18–45 · Women only · Healthy volunteers
Aysegul Kilicli · Sites in Turkey
Ages 19–49 · Women only · Healthy volunteers
Umraniye Education and Research Hospital · Sites in Turkey
Ages 18–39 · Women only
Hatice Nur Nefes Pala · Sites in Turkey
Ages 18+ · Women only · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 96 is below the median of 110 across 482 interventional studies indexed under Pre-Eclampsia.
Median enrollment 84 across the 19 interventional studies, 96 across the 31 observational. Of the 31 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 50 has an industry lead sponsor. The 10 most frequent:
Istanbul University - Cerrahpasa is the lead sponsor of 702 studies on the registry; 212 are open to participants now.
Istanbul University - Cerrahpasa has 6 studies filed under Pre-Eclampsia — fewer than ten, so there is no comparison to draw.
2 of the studies in Pre-Eclampsia with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07874191Muğla Sıtkı Koçman UniversityRetinal and Choroidal Microcirculation in Preeclampsia: An OCTA Study | 2026-12-29 |
| NCT07745036Samsun UniversityRole of Progesterone Membrane Receptors in the Pathogenesis of Preeclampsia | 2027-01-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 50 studies in Pre-Eclampsia with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Preeclampsia, affecting 2-8% of pregnancies globally, is a leading hypertensive disorder in pregnancy. It is clinically characterized by elevated blood pressure (≥140/90 mmHg) after the 20th gestational week, often accompanied by proteinuria and systemic complications such as thrombocytopenia, liver dysfunction, and cerebral symptoms. This condition poses significant risks for both maternal and fetal health, increasing the likelihood of organ damage, preterm birth, and long-term cardiovascular and neurodevelopmental complications. Non-pharmacological interventions, including relaxation techniques, have been explored for symptom management. Progressive muscle relaxation (PMR) has shown efficacy in reducing stress, anxiety, and blood pressure. Recently, virtual reality (VR)-based relaxation techniques have gained attention for enhancing stress relief and improving health outcomes. This study aims to compare the effects of VR-based PMR with in-person PMR on maternal and fetal outcomes in preeclamptic pregnancies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Withdrawal Criteria:
Participants in this group will engage in 15-minute progressive muscle relaxation (PMR) exercises guided by the researcher for three consecutive days (once per day). To promote continued practice, participants will receive an audio recording of the PMR session, narrated by the researcher. After the initial three supervised sessions, they will be asked to listen to this recording twice a week and log their practice on a provided tracking sheet. The researcher will follow up with participants via phone calls to monitor compliance.
Other: Face-to-Face Progressive Muscle Relaxation
Participants will undergo 15-minute VR-assisted PMR sessions for three consecutive days (once per day) under the researcher's supervision. During the VR sessions, participants will be exposed to relaxing nature scenes and sounds while simultaneously engaging in researcher-guided progressive muscle relaxation (PMR) exercises. After the initial three sessions, participants will receive an audio recording of the PMR session and will be instructed to listen to it twice a week, logging their sessions. The researcher will conduct phone follow-ups to ensure adherence.
Other: Virtual Reality Based Progressive Muscle Relaxation
Participants in the control group will not receive any relaxation intervention and will continue their usual daily routines.
Participants engage in progressive muscle relaxation exercises using a virtual reality headset that provides immersive visual and auditory relaxation content. Sessions are conducted under researcher supervision, followed by self-guided practice using an audio recording.
Participants practice progressive muscle relaxation exercises in a traditional face-to-face setting, guided by a researcher. Initial supervised sessions are complemented by self-guided practice using an audio recording.
Descriptive Information Form
A researcher-developed questionnaire designed to collect sociodemographic and obstetric data based on the literature.
Time frame: Day 1 (Baseline, Pre-Intervention)
Maternal-Fetal Outcomes Follow-up Form
Tracked using a researcher-developed follow-up form, including maternal vital signs and Non-Stress Test (NST) parameters.
Time frame: Day 1 (Baseline, Pre-Intervention), Day 2 and 3 (Post-Intervention for intervention groups, routine monitoring for the control group)
Beck Anxiety Inventory (BAI)
Developed by Beck, Steer, Epstein, and Brown in 1988 and adapted into Turkish by Ulusoy et al. in 1998, this 21-item Likert-type scale measures anxiety levels. Each item is scored between 0 and 3, with total scores ranging from 0 to 63. Higher scores indicate higher levels of anxiety. The Turkish version has a Cronbach's alpha of 0.93, indicating high internal consistency. Factor analysis suggests two subscales: Subjective Symptoms and Somatic Symptoms.
Time frame: Day 1 (Baseline, before intervention for intervention groups, before routine assessment for control group) and Day 3 (Post-intervention for intervention groups, after routine assessment for control group).
Prenatal Comfort Scale (PCS)
Originally developed by Takeishi et al. in 2011 in Japan and later revised by Nakamura et al. in 2015 to a 15-item version, this scale measures prenatal comfort across five subscales: Partner's Role in Fatherhood, Fetal Interaction, Social Support, Maternal Role Adaptation, and Awareness of Pregnancy Changes. The 6-point Likert-type scale ranges from 0 (strongly disagree) to 5 (strongly agree), with higher scores indicating higher comfort levels. The scale has a Cronbach's alpha of 0.95 in the original study and 0.82 in the Turkish adaptation.
Time frame: Day 1 (Baseline, before intervention for intervention groups, before routine assessment for control group) and Day 3 (Post-intervention for intervention groups, after routine assessment for control group).
Heart Rate Variability (HRV) Measurement via Photoplethysmography (PPG)
A non-invasive test used to assess physiological stress levels by measuring heart rate variability (HRV) through a photoplethysmography (PPG) sensor placed on the fingertip.
Time frame: Day 1 (Baseline, before the relaxation intervention) and Day 3 (Post-intervention, after the relaxation session).
Satisfaction Evaluation Form (VAS)
A researcher-developed form assessing participants' overall satisfaction with the intervention, perceived anxiety and stress reduction, and general experience. (only for intervention groups)
Time frame: Day 3 (Post-Intervention)
Edinburgh Postpartum Depression Scale (EPDS)
eveloped by Cox et al. in 1987 and adapted into Turkish by Engindeniz et al. in 1996, this 10-item, 4-point Likert-type self-report scale assesses postpartum depression risk. Scores range from 0 to 30, with a cut-off point of 13. Internal consistency in the Turkish adaptation is 0.79, with a sensitivity of 0.84 and specificity of 0.88.
Time frame: Up to 4-6 weeks postpartum (via phone follow-up)
Postpartum Evaluation Form
A researcher-developed form assessing delivery type, maternal and neonatal health parameters, and newborn evaluations based on literature
Time frame: Up to 4-6 weeks postpartum (via phone follow-up)
Plan to share: No — Individual participant data (IPD) will be stored in an online database (e.g., Mendeley). Data will be available upon request after the study results are published by the researchers.
Started Sep 2025 (actual). Primary completion is estimated for Sep 2026, 11 months after the start.
Of 172 non-industry interventional studies with no phase under Pre-Eclampsia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 11 months is below that.
Counting every sponsor, half of 177 studies reached it within 24 months; a quarter within 10 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istanbul University - Cerrahpasa →